Bio-Rad reports third-quarter 2026 financial results
FROM THE WIRE · BUSINESSWIRE.COM
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the third quarter ended September 30, 2026. Norman Schwartz, Bio-Rad's Chief…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishQuarterly results with a return to currency-neutral revenue growth, relevant for the stock.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Bio-Rad returned to currency-neutral revenue growth.
- 02Growth was led by the Clinical Diagnostics division.
- 03CEO Norman Schwartz cites strong demand for Droplet Digital.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets